Virtus Biotech ETF
BBP
12 hedge funds and large institutions have $2.74M invested in Virtus Biotech ETF in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
42% more capital invested
Capital invested by funds: $1.94M → $2.74M (+$805K)
9% more funds holding
Funds holding: 11 → 12 (+1)
2.83% more ownership
Funds ownership: 12.91% → 15.74% (+2.8%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$222K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$209K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$22.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$17.9K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6.17K |
BBP Hedge Fund Activity: Q4 2023 in Review
12 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q4 2023, worth a combined $2.74M — up 42% from $1.94M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BBP positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $222K. The largest seller was LPL Financial, cutting an estimated $17.9K.
- 12 institutional investors held Virtus Biotech ETF (BBP) as of Q4 2023, up from 11 in Q3 2023.
- Funds reported $2.74M of Virtus Biotech ETF stock for Q4 2023, up 42% quarter-over-quarter.
- 1 fund opened new Virtus Biotech ETF positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest Virtus Biotech ETF buyer in Q4 2023 was Morgan Stanley, an estimated $222K added.
- The largest Virtus Biotech ETF seller in Q4 2023 was LPL Financial, an estimated $17.9K sold.
Based on aggregated 13F filings for Q4 2023.